Abstract
As a natural active substance that can effectively improve blood lipid balance in the body, hypolipidemic active peptides have attracted the attention of scholars. In this study, the effect of walnut meal peptides (WMP) on lipid metabolism was investigated in rats fed a high-fat diet (HFD). The experimental results show that feeding walnut meal peptides counteracted the high-fat diet-induced increase in body, liver and epididymal fat weight, and reduce the serum concentrations of total cholesterol, triglycerides, and LDL-cholesterol and hepatic cholesterol and triglyceride content. Walnut meal peptides also resulted in increased HDL-cholesterol while reducing the atherosclerosis index (AI). Additionally, the stained pathological sections of the liver showed that the walnut meal peptides reduced hepatic steatosis and damage caused by HFD. Furthermore, walnut meal peptide supplementation was associated with normalization of elevated apolipoprotein (Apo)-B and reduced Apo-A1 induced by the high-fat diet and with favorable changes in the expression of genes related to lipid metabolism (LCAT, CYP7A1, HMGR, FAS). The results indicate that walnut meal peptides can effectively prevent the harmful effects of a high-fat diet on body weight, lipid metabolism and liver fat content in rats, and provide, and provide a reference for the further development of walnut meal functional foods.
Highlights
IntroductionObesity and metabolic syndrome are becoming more prevalent in developing countries as economic development increases, mainly due to accelerated urbanization, nutritional transformation and reduced physical activity, as well as genetic factors [1,2]
We further investigated the effect of walnut meal peptides on the lipid metabolism marker enzymes in high-fat diet (HFD)-induced obese rats, including fatty acid synthase (FAS), HMGCoA reductase (HMGR), lecithin cholesterol acyltransferase (LCAT) and cholesterol 7αhydroxylase (CYP7A1)
The hypolipidemic activity of walnut meal peptides may be closely related to the composition of amino acid and hydrophobicity
Summary
Obesity and metabolic syndrome are becoming more prevalent in developing countries as economic development increases, mainly due to accelerated urbanization, nutritional transformation and reduced physical activity, as well as genetic factors [1,2]. The current anti-obesity drugs, including orlistat, locasserin, and sustainedrelease tablets of phentermine/topiramate, naltrexone/bupropion exhibit some degree of efficacy at weight loss [6,7]. These anti-obesity drugs show side effects, such as gastrointestinal diseases, weakness, mental disorders, cardiovascular diseases, and so on [8]. Many experts expect to obtain hypolipidemic active factors from natural products to intervene in obesity and its related complications in addition to direct drug treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
